For example, it is likely that groups investigating the prognostic significance of inflammatory biomarkers in patients with advanced/metastatic NSCLC expressing PD-L1 ≥ 50% treated with pembrolizumab also treat patients expressing PD-L1 < 50% with chemoimmunotherapy regimens. This evidence concerns the gene CD274 and non-small cell lung carcinoma.